anti-interleukin-6 - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.07 [0.59, 1.94]< 155%4 studies (4/-)40.9 %some concernnot evaluable moderatecrucial-
death or transfer to ICU 0.97 [0.50, 1.88]< 10%1 study (1/-)53.6 %lownot evaluable highcrucial-
deaths 0.86 [0.77, 0.96]< 12%13 studies (13/-)99.7 %some concernlow moderatecrucial-
deaths (time to event analysis only) 0.90 [0.56, 1.45]< 137%3 studies (3/-)66.3 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.76 [0.56, 1.05]< 116%5 studies (5/-)95.1 %some concernnot evaluable moderateimportant-
clinical improvement 1.21 [1.03, 1.43]> 133%6 studies (6/-)98.8 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.11 [0.95, 1.31]> 10%3 studies (3/-)90.2 %some concernnot evaluable moderateimportant-
death or ventilation 0.79 [0.65, 0.95]< 120%6 studies (6/-)99.3 %some concernnot evaluable moderateimportant-
hospital discharge 1.16 [0.90, 1.49]> 10%1 study (1/-)87.9 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.76 [0.54, 1.09]< 10%4 studies (4/-)93.4 %some concernnot evaluable moderateimportant-
ICU admission 0.85 [0.49, 1.49]< 157%3 studies (3/-)71.2 %some concernnot evaluable moderatenon important-
recovery 0.64 [0.14, 2.92]> 10%1 study (1/-)28.3 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 1.06 [0.83, 1.37]< 10%8 studies (8/-)31.2 %some concernserious moderateimportant-
adverse events 1.44 [0.92, 2.24]< 164%6 studies (6/-)5.5 %some concernserious moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.